Predict your next investment

Private Equity
FINANCIAL | Asset/Financial Management
metalmarkcapital.com

See what CB Insights has to offer

Investments

72

Portfolio Exits

49

Funds

4

Service Providers

2

About Metalmark Capital

Metalmark Capital is a private equity financing firm. The Firm primarily invests in business services, growth industrials, energy, and healthcare. Metalmark Capital seeks to build long-term value through active and supportive partnerships with the companies and management teams in which it invests.

Metalmark Capital Headquarter Location

1177 Ave of the Americas 40th Floor

New York, New York, 10036,

United States

212-823-1931

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Metalmark Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Metalmark Capital in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Metalmark Capital Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Metalmark Capital Rank

Latest Metalmark Capital News

Jasper Therapeutics And Amplitude Healthcare Acquisition Corporation Announce Two New Board Members

Sep 20, 2021

Jasper Therapeutics And Amplitude Healthcare Acquisition Corporation Announce Two New Board Members Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, and Amplitude Healthcare Acquisition Corporation (Nasdaq: AMHCU), a special purpose acquisition company (SPAC) sponsored by affiliates of Avego... Author: Sep 20, 2021 2:22 PM EDT Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, and Amplitude Healthcare Acquisition Corporation (Nasdaq: AMHCU), a special purpose acquisition company (SPAC) sponsored by affiliates of Avego Management, LLC and Metalmark Capital, today announced that Lawrence Klein, Ph.D., and Chris Nolet will be appointed to Jasper Therapeutics' board of directors, effective upon closing of the pending merger between the parties. Mr. Nolet will assume the role of Audit Committee Chair. "We are pleased to appoint Lawrence and Chris to the Jasper board of directors to add additional expertise to the team in cellular and gene therapy development and to build a leading public biotechnology company," said Bill Lis, executive chairman and chief executive officer of Jasper Therapeutics. "We look forward to their input and guidance as we advance the clinical development of JSP191, our anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning agent, and our novel engineered stem cell platform, which aims to expand the number of patients who could benefit from allogeneic and autologous gene edited hematopoietic stem cell therapy." Dr. Klein currently serves as chief operating officer at CRISPR Therapeutics, where he previously served as senior vice president and head of strategy and business development. Before joining CRISPR, he was an associate partner at McKinsey & Company, where he was a leader in the biotech practice and served a number of biotech companies on a wide range of topics from strategy to operations. He earned a B.S. in biochemistry and physics from the University of Wisconsin-Madison and a Ph.D. in biophysics from Stanford University. Mr. Nolet has extensive experience as a long-time audit partner and business advisor in the life sciences industry. He currently serves on the boards of three publicly-traded life science companies and the board a life science industry organization. He is the former West Region Life Sciences Industry Leader and Partner at Ernst & Young (EY), having retired in June 2019 after more than 38 years in the profession. In addition to serving clients, his responsibilities included leading the West Region EY Life Sciences Industry Group and serving as a member of the Global EY Life Sciences Executive Leadership Group, which established policies and operating strategies for the EY Life Sciences practice worldwide. Prior to joining EY, Mr. Nolet was ​a partner at PricewaterhouseCoopers, where he led the life sciences practice in the western U.S. He holds a B.S. in accounting from San Diego State University and ​is​ a certified public accountant in California (retired). About Jasper Therapeutics Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, an anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It is designed to enable safer and more effective curative allogeneic and autologous hematopoietic cell transplants and gene therapies. In parallel, Jasper Therapeutics is advancing its preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible today. For more information, please visit us at jaspertherapeutics.com . About Amplitude Healthcare Acquisition Corporation Amplitude was founded by Avego and Metalmark to seek innovative private life sciences company acquisition targets. We leverage our management and board's reputation, experience, and track record of making investments and creating value in the industry. We have a strong history of building and growing companies as constructive and trustworthy partners. For more information, please visit: https://www.amplitudehealthcare.com . Forward Looking Statements This press release contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed business combination between Jasper Therapeutics, Inc. and Amplitude Healthcare Acquisition Corporation, the proposed appointment of Lawrence Klein, Ph.D., and Chris Nolet to the Jasper Therapeutics' board of directors, effective upon closing of the pending merger between the parties and Jasper Therapeutics' products, technologies and prospects. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "forecast," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions (including the negative versions of such words or expressions). Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the risk that the proposed business combination may not be completed in a timely manner or at all; (ii) the failure to satisfy the conditions to the consummation of the proposed business combination; (iii) the effect of the announcement or pendency of the proposed business combination on Jasper Therapeutics' business relationships, performance, and business generally; and (iv) the ability to implement business plans, forecasts, and other expectations after the completion of the proposed business combination, and identify and realize additional opportunities. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in Amplitude Healthcare Acquisition Corporation final proxy statement/information statement/prospectus contained in the Form S-4 registration statement described below, including those under "Risk Factors" therein, Quarterly Reports on Form 10-Q and other documents filed by Amplitude Healthcare Acquisition Corporation from time to time with the U.S. Securities and Exchange Commission (the "SEC"). These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Jasper Therapeutics, Inc. and Amplitude Healthcare Acquisition Corporation assume no obligation and, except as required by law, do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Jasper Therapeutics, Inc. nor Amplitude Healthcare Acquisition Corporation gives any assurance that either Jasper Therapeutics, Inc. or Amplitude Healthcare Acquisition Corporation will achieve its expectations. Additional Information and Where to Find It In connection with the proposed business combination between Jasper Therapeutics, Inc. and Amplitude Healthcare Acquisition Corporation, the registration statement on Form S-4 has been declared effective by the SEC. That registration statement includes the related proxy statement and prospectus of Amplitude Healthcare Acquisition Corporation with respect to Amplitude Healthcare Acquisition Corporation's special meeting of stockholders. Amplitude Healthcare Acquisition Corporation's stockholders and other interested persons are advised to read the registration statement and the related proxy statement/prospectus and any documents filed in connection therewith, as these materials will contain important information about Jasper Therapeutics, Inc., Amplitude Healthcare Acquisition Corporation and the proposed business combination. The definitive proxy statement and related materials have been mailed to Amplitude Healthcare Acquisition Corporation's stockholders who were holders of record as of the close of business on August 20, 2021 . Investors and security holders may obtain free copies of the proxy statement/information statement/prospectus and all other relevant documents filed with the SEC by Amplitude Healthcare Acquisition Corporation through the website maintained by the SEC at www.sec.gov . In addition, the documents filed by Amplitude Healthcare Acquisition Corporation may be obtained free of charge by directing a request to Amplitude Healthcare Acquisition Corporation, 1177 Avenue of the Americas, Fl 40, New York, New York 10036. Disclaimer This communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy, any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed business combination or otherwise, nor shall there be any sale, issuance or transfer or securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005843/en/ By

Metalmark Capital Investments

72 Investments

Metalmark Capital has made 72 investments. Their latest investment was in Valagro as part of their Private Equity - II on June 6, 2019.

CBI Logo

Metalmark Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/25/2019

Private Equity - II

Valagro

No

1

3/15/2019

Private Equity - II

Annovis Bio

$0.53M

No

1

12/7/2018

Private Equity

T. Parker Host

Yes

1

12/22/2017

Private Equity

Subscribe to see more

$99M

Subscribe to see more

10

10/17/2016

Private Equity

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/25/2019

3/15/2019

12/7/2018

12/22/2017

10/17/2016

Round

Private Equity - II

Private Equity - II

Private Equity

Private Equity

Private Equity

Company

Valagro

Annovis Bio

T. Parker Host

Subscribe to see more

Subscribe to see more

Amount

$0.53M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

10

Metalmark Capital Portfolio Exits

49 Portfolio Exits

Metalmark Capital has 49 portfolio exits. Their latest portfolio exit was Nexant on May 12, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/12/2021

Acquired

1

10/6/2020

Acquired

2

2/3/2020

Acquired

$991

2

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

5/12/2021

10/6/2020

2/3/2020

00/00/0000

00/00/0000

Exit

Acquired

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

2

2

10

10

Metalmark Capital Acquisitions

23 Acquisitions

Metalmark Capital acquired 23 companies. Their latest acquisition was WorldStrides on February 11, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/11/2016

Acq - Fin - II

$991

$26.15M

Acq - Fin - II

3

4/20/2015

Acq - Fin

Acq - Fin

6

4/16/2014

Leveraged Buyout

Merger

1

4/16/2014

Subscribe to see more

$99M

Subscribe to see more

10

1/5/2012

Acq - Fin - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/11/2016

4/20/2015

4/16/2014

4/16/2014

1/5/2012

Investment Stage

Acq - Fin - II

Acq - Fin

Leveraged Buyout

Acq - Fin - II

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

Total Funding

$26.15M

$99M

$99M

Note

Acq - Fin - II

Acq - Fin

Merger

Subscribe to see more

Subscribe to see more

Sources

3

6

1

10

10

Metalmark Capital Fund History

4 Fund Histories

Metalmark Capital has 4 funds, including Metalmark Capital Partners II LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/6/2012

Metalmark Capital Partners II LP

Buyouts & Acquisitions

$2,500M

1

4/2/2012

Metalmark Capital Partners II Executive Fund LP

Subscribe to see more

$99M

10

10/31/2006

Metalmark Capital Partners LP

Subscribe to see more

$99M

10

Metalmark Capital Partners Cayman III

Subscribe to see more

$99M

10

Closing Date

4/6/2012

4/2/2012

10/31/2006

Fund

Metalmark Capital Partners II LP

Metalmark Capital Partners II Executive Fund LP

Metalmark Capital Partners LP

Metalmark Capital Partners Cayman III

Fund Type

Buyouts & Acquisitions

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Amount

$2,500M

$99M

$99M

$99M

Sources

1

10

10

10

Metalmark Capital Service Providers

2 Service Providers

Metalmark Capital has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - Fin

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Acq - Fin

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Partnership data by VentureSource

Metalmark Capital Team

7 Team Members

Metalmark Capital has 7 team members, including current Chief Executive Officer, Howard Hoffen.

Name

Work History

Title

Status

Howard Hoffen

Chief Executive Officer

Current

Kenneth F. Clifford

Morgan Stanley Capital Partners, and Morgan Stanley

Chief Financial Officer

Current

Michael C. Hoffman

Managing Director

Current

Mian Fazle Husain

Managing Director

Current

Jeffrey Siegal

Managing Director

Current

Name

Howard Hoffen

Kenneth F. Clifford

Michael C. Hoffman

Mian Fazle Husain

Jeffrey Siegal

Work History

Morgan Stanley Capital Partners, and Morgan Stanley

Title

Chief Executive Officer

Chief Financial Officer

Managing Director

Managing Director

Managing Director

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.